CA Patent

CA2454675C — 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents

Assigned to Cassiopea SpA · Expires 2009-05-26 · 17y expired

What this patent protects

17.alpha.,21-Dihydroxypregna-4,9-diene-3,20-dione and 17.alpha.,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters of having remarkable antiandrogenic activity, and the processes for the preparation thereof.

USPTO Abstract

17.alpha.,21-Dihydroxypregna-4,9-diene-3,20-dione and 17.alpha.,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters of having remarkable antiandrogenic activity, and the processes for the preparation thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA2454675C
Jurisdiction
CA
Classification
—
Expires
2009-05-26
Drug substance claim
No
Drug product claim
No
Assignee
Cassiopea SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.